Grupo Galego de Investigaciones Oncolóxicas
GIO
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (19)
2023
-
Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease
Revista Espanola de Patologia, Vol. 56, Núm. 3, pp. 158-167
-
“Long-term oncologic outcomes and risk factors for distant recurrence after pathologic complete response following neoadjuvant treatment for locally advanced rectal cancer. A nationwide, multicentre study”
European Journal of Surgical Oncology, Vol. 49, Núm. 10
2021
2019
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
-
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry
Leukemia and Lymphoma, Vol. 60, Núm. 11, pp. 2720-2732
2018
-
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 1, pp. 146-154
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
-
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84
2015
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
2013
-
Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)
Medical Mycology, Vol. 51, Núm. 2, pp. 150-154
-
Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952
2011
-
Invasive fungal infections in onco-haematology: A spanish perspective
Revista Espanola de Quimioterapia, Vol. 24, Núm. 3, pp. 168-172
2009
-
Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation
Atherosclerosis, Vol. 205, Núm. 2, pp. 561-567
2007
-
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
Leukemia, Vol. 21, Núm. 1, pp. 143-150
-
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
European Journal of Haematology, Vol. 78, Núm. 2, pp. 102-110
2006
-
Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: Frequency and prognosis in 467 patients without cranial irradiation for prophylaxis
Cancer, Vol. 106, Núm. 12, pp. 2540-2546
-
Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes
Medicina Clinica, Vol. 126, Núm. 2, pp. 41-46